Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: A Phase III, randomized, double-blind, placebo-controlled study

Nephrology Dialysis Transplantation

Volumn 25, Issue 4, 2010, Pages 1251-1257

  Kumagai, Hiroo ^a   Ebata, Toshiya ^b   Takamori, Kenji ^b   Muramatsu, Taro ^c   Nakamoto, Hidetomo ^d   Suzuki, Hiromichi ^d  

^a National Defense Medical College   (Canada)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d SAITAMA MEDICAL UNIVERSITY HOSPITAL   (Japan)

Author keywords

receptor agonist; Itch; Nalfurafine hydrochloride; Randomized controlled study; Visual analogue scale

Indexed keywords

ANTIHISTAMINIC AGENT; NALFURAFINE; PLACEBO;

ABNORMAL SENSATION; ADULT; ANOREXIA; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EOSINOPHIL COUNT; EVENING DOSAGE; FEMALE; FREE THYROXINE INDEX; HEADACHE; HEMODIALYSIS; HUMAN; HYPERTENSION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MOOD; MORNING DOSAGE; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROSPECTIVE STUDY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE; SUDDEN DEAFNESS; TESTOSTERONE BLOOD LEVEL; THYROTROPIN BLOOD LEVEL; TREATMENT DURATION; VISUAL ANALOG SCALE; VOMITING;

DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MORPHINANS; PLACEBOS; PROSPECTIVE STUDIES; PRURITUS; RECEPTORS, OPIOID, KAPPA; RENAL DIALYSIS; SPIRO COMPOUNDS; TREATMENT OUTCOME;

EID: 77950267997     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp588     Document Type: Article

References (26)

1. Ikoma A, Steinhoff M, Ständer S, et al. The neurobiology of itch. Nat Rev Neurosci 2006; 7: 535-547
2. Schwartz I.F, Iaina A. Uraemic pruritus. Nephrol Dial Transplant 1999; 14: 834-839
3. Mettang T, Pauli-Magnus U, Alscher DM. Uraemic pruritus: new perspectives and insights from recent trials. Nephrol Dial Transplant 2002; 17: 1558-1563
4. Yosipovitch G, Greaves MW, Schmelz M. Itch. Lancet 2003; 361: 690-694
5. Patel TS, Freedman BI, Yosipovitch G. An update on pruritus associated with CKD. Am J Kidney Dis 2007; 50: 11-20
6. Pisoni R, Wikström B, Akizawa T, et al. Pruritus in haemodialysis patients: international results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2006; 21: 3495-3505
7. Narita I, Omori K, Gejyo F, et al. Etiology and prognostic significance of severe uremic pruritus in chronic hemodialysis patients. Kidney Int 2006; 69: 1626-1632
8. Peer G, Kivity S, Aqami O, et al. Randomised crossover trial of naltrexone in uraemic pruritus. Lancet 1996; 348: 1552-1554
9. Pauli-Magus C, Mikus T, Mettang T, et al. Naltrexone does not relieve uremic pruritus: results of a randomized, placebo-conrolled crossover-study. J Am Soc Nephrol 2000; 11: 514-519
10. Gunter JB, McAuliffe J, Gregg T, et al. Continuous epidural butorpha-nol relieves pruritus associated with epidural morphine infusions in children. Paediatr Anaesth 2000; 10: 167-172
11. Dawn AG, Yosipovitch G. Butorphanol for treatment of intractable pruritus. J Am Acad Dermatol 2006; 54: 527-531
12. Kumagai H, Matsukawa S, Saruta T, et al. Prospects for a novel κ-opioid receptor agonist, TRK-820, in uremic pruritus. In: G Yosipo-vitch (ed). Itch. Basic Mechanisms and Therapy. New York, USA: Marcel Dekker, 2004; 279-286
13. Pan ZZ μ-Opposing actions of the κ-opioid receptor. Trends Pharmacol Sci 1998; 19: 94-98
14. Seki T, Awamura S, Kimura C, et al. Pharmacological properties of TRK-820 on cloned mu-, delta-and kappa-opioid receptors and no-ciceptin receptor. Eur J Pharmacol 1999; 376: 159-167
15. Nagase H, Hayakawa J, Kawamura K, et al. Discovery of a structurally novel opioid kappa-agonist derived from 4, 5-epoxymorphinan. Chem Pharm Bull 1998; 46: 366-369
16. Wakasa Y, Fujiwara A, Umeuchi H, et al. Inhibitory effects of TRK-820 on systemic skin scratching induced by morphine in rhesus monkeys. Life Sci 2004; 75: 2947-2957
17. Togashi Y, Umeuchi H, Okano K, et al. Antipruritic activity of the kappa-opioid receptor agonist, TRK-820. Eur J Pharmacol 2002; 435: 259-264
18. Wikström B, Gellert R, Ladefoged SD, et al. Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies. J Am Soc Nephrol 2005; 16: 3742-3747
19. Wahlgren CF, Ekblom A, Hägermark O. Some aspects of the experimental induction and measurement of itch. Acta Derm Venereol 1989; 69: 185-189
20. Delmez JA. Efficacy and safety of a new kappa-opioid receptor agonist for the treatment of uremic pruritus. Nat Clin Pract Nephrol 2006; 2: 358-359
21. Umeuchi H, Togashi Y, Nagase H, et al. Involvement of central μ-opi-oid system in the scratching behavior in mice, and the suppression of it by the activation of κ-opioid system. Eur J Pharmacol 2003; 477: 29-35
22. Kamei J, Nagase H. Norbinaltorphimine, a selective κ-opioid receptor antagonist, induces an itch-associated response in mice. Eur J Pharmacol 2001; 418: 141-145
23. Kuraishi Y, Yamaguchi T, Miyamoto T. Itch-scratch responses induced by opioids through central mu opioid receptors in mice. J Biomed Sci 2000; 7: 248-252
24. Bigliardi PL, Bigliardi-Qi M, Buechner S, et al. Expression of m-opiate receptor in human epidermis and keratinocytes. J Invest Dermatol 1998; 111: 297-301
25. Bigliardi PL, Strammer H, Jost G, et al. Treatment of pruritus with topically applied opiate receptor antagonist. J Am Acad Dermatol 2007; 56: 979-988
26. Tominaga M, Ogawa H, Takamori K. Possible roles of epidermal opioid systems in pruritus of atopic dermatitis. J Invest Dermatol 2007; 127: 2228-2235